The Role of Circulating Tight Junction Proteins in Evaluating Blood Brain Barrier Disruption following Intracranial Hemorrhage
Table 3
Circulating TJs and cytokines in patients with intracranial hemorrhage and the controls.
Intracranial hemorrhage
Controls
CLDN5 (pg/mL)
1302.35 (669.72–2103.04)
157.28 (107.48–213.82)
CLDN5 (pg/mL)
89.62 (80.18–117.07)
125.79 (103.07–125.79)
OCLN (pg/mL)
10.30 (7.22–14.26)
0.55 (0.39–1.48)
OCLN (pg/mL)
12.56 (8.75–13.54)
10.95 (9.63–10.95)
ZO-1 (pg/mL)
934.46 (712.03–1161.35)
181.08 (138.46–214.08)
ZO-1 (pg/mL)
2007.96 (1506.78–2647.24)
2173.48 (1678.81–2173.48)
CLDN5/OCLN
145.55 (75.62–225.66)
268.65 (116.65–452.29)
CLDN5/OCLN
7.77 (6.24–12.02)
11.48 (10.70–13.26)
CLDN5/ZO-1
1.34 (0.76–2.08)
0.93 (0.57–1.39)
CLDN5/ZO-1
0.0489 (0.0413–0.0587)
0.0579 (0.0403–0.0579)
VEGF (ng/mL)
33.16 (25.42–87.43)
9.21 (8.38–10.03)
MMP-9 (ng/mL)
0.29 (0.20–0.69)
0.10 (0.09–0.13)
CLDN5: serum Claudin-5; OCLN: serum Occludin; ZO-1: serum ZO-1; CSF: cerebrospinal fluid; CLDN5: Claudin-5 in CSF; OCLN: OCLN in CSF; ZO-1: ZO-1 in CSF; VEGF: vascular endothelial growth factor; MMP-9: metalloproteinases. when the intracranial hemorrhage group is compared with control.